Increased wild-type p53-induced phosphatase 1 (Wip1 or PPM1D) expression correlated with downregulation of checkpoint kinase 2 in human gastric carcinoma

Pathology International

Volumn 57, Issue 9, 2007, Pages 566-571

  Fuku, Takeichi ^a   Semba, Shuho ^a   Yutori, Hirokazu ^a   Yokozaki, Hiroshi ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cdc25C; Chk2; Gastric cancer; Wip1 (PPM1D); Z Leu Leu Leu (ZLLL)

Indexed keywords

CHECKPOINT KINASE 2; PHOSPHATASE; PROTEIN P53; PROTEIN WIP1; PROTEINASE INHIBITOR; TRIPEPTIDE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER SIZE; CARCINOMA CELL; CELL CYCLE REGULATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; EMBRYO; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IONIZING RADIATION; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; STOMACH CARCINOMA; STOMACH EPITHELIUM; UPREGULATION; WILD TYPE;

ADENOCARCINOMA; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; CYSTEINE PROTEINASE INHIBITORS; ENZYME INDUCTION; FEMALE; GASTRIC MUCOSA; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; LEUPEPTINS; MALE; PHOSPHOPROTEIN PHOSPHATASE; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN-SERINE-THREONINE KINASES; RADIATION, IONIZING; STOMACH NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34547681215     PISSN: 13205463     EISSN: 14401827     Source Type: Journal    
DOI: 10.1111/j.1440-1827.2007.02140.x     Document Type: Article

References (26)

1. Zhou BB, Elledge SJ. The DNA damage response: Putting checkpoints in perspective. Nature 2000 408 : 433 9.
2. Goodarzi AA, Jonnalagadda JC, Douglas P et al. Autophosphorylation of ataxia-telangiectasia mutated is regulated by protein phosphatase 2A. EMBO J 2004 23 : 4451 61.
3. Lukas C, Falck J, Bartkova J, Bartek J, Lukas J. Distinct spatiotemporal dynamics of mammalian checkpoint regulators induced by DNA damage. Nat Cell Biol 2003 5 : 255 60.
4. Matsuoka S, Rotman G, Ogawa A, Shiloh Y, Tamai K, Elledge SJ. Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. Proc Natl Acad Sci USA 2000 97 : 10 89 94.
5. Melchionna R, Chen XB, Blasina A, McGowan CH. Threonine 68 is required for radiation-induced phosphorylation and activation of Cds1. Nat Cell Biol 2000 2 : 762 5.
6. Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 2003 3 : 421 9.
7. Lee SB, Kim SH, Bell DW et al. Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni syndrome. Cancer Res 2001 61 : 8062 7.
8. Craig AL, Hupp TR. The regulation of CHK2 in human cancer. Oncogene 2004 23 : 8411 18.
9. Fiscella M, Zhang H, Fan S et al. Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. Proc Natl Acad Sci USA 1997 94 : 6048 53.
10. Takekawa M, Adachi M, Nakahata A et al. p53-inducible Wip1 phosphatase mediates a negative feedback regulation of p38 MAPK-p53 signaling in response to UV radiation. EMBO J 2000 19 : 6517 26.
11. Lu X, Nannenga B, Donehower LA. PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints. Genes Dev 2005 19 : 1162 74.
12. Oliva-Trastoy M, Berthonaud V, Chevalier A et al. The Wip1 phosphatase (PPM1D) antagonizes activation of the Chk2 tumor suppressor kinase. Oncogene 2007 26 : 1449 58.
13. Hirasawa A, Saito-Ohara F, Inoue J et al. Association of 17q21-q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification of PPM1D and APPBP2 as likely amplification targets. Clin Cancer Res 2003 9 : 1995 2004.
14. Saito-Ohara F, Imoto I, Inoue J et al. PPM1D is a potential target for 17q gain in neuroblastoma. Cancer Res 2003 63 : 1876 83.
15. Sinclair CS, Rowley M, Naderi A, Couch FJ. The 17q23 amplicon and breast cancer. Breast Cancer Res Treat 2003 78 : 313 22.
16. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma-2nd English Edition: Response assessment of chemotherapy and radiotherapy for gastric carcinoma: Clinical criteria. Gastric Cancer 2001 4 : 1 8.
17. Sobin LH, Wittekind CH. UICC TNM Classification of Malignant Tumor, 5th edn. New York : John Wiley and Sons, 1997.
18. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998 396 : 643 9.
19. Gorgoulis VG, Vassiliou LV, Karakaidos P et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005 434 : 907 13.
20. Roos WP, Kaina B. DNA damage-induced cell death by apoptosis. Trends Mol Med 2006 12 : 440 50.
21. Haruki N, Saito H, Tatematsu Y et al. Histological type-specific, tumor-predominant expression of a novel CHK1 isoform and infrequent in vivo somatic CHK2 mutation in small cell lung cancer. Cancer Res 2000 60 : 4689 92.
22. The CHEK2-Breast Cancer Consortium. Low-penetrance susceptibility to breast cancer due to CHEK2*1100dleC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 2002 31 : 55 9.
23. Wu X, Dong X, Liu W, Chen J. Characterization of CHEK2 mutations in prostate cancer. Hum Mutat 2006 27 : 742 7.
24. Bulavin DV, Demidov ON, Saito S et al. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet 2002 31 : 210 15.
25. Nannenga B, Lu X, Dumble M et al. Augmented cancer resistance and DNA damage response phenotypes in PPM1D null mice. Mol Carcinog 2006 45 : 594 604.
26. Shreeram S, Demidov ON, Hee WK et al. Wip1 phosphatase modulates ATM-dependent signaling pathway. Mol Cell 2006 23 : 757 64.